Timothy J. Thauland

Timothy J. Thauland

Auto-generated profile, based on publicly available information

Timothy J. Thauland

University of California, Los Angeles 1 Division of Allergy, Immunology & Rheumatology, Department of Pediatrics Los Angeles, CA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KMKevin P. Meng
Kevin P. Meng
FMFatemeh S. Majedi
Fatemeh S. Majedi
TTTimothy J. Thauland
Timothy J. Thauland
MBManish J Butte
Manish J Butte
Upon immunogenic challenge, lymph nodes become mechanically stiff as immune cells activate and proliferate within their encapsulated environments, and with resolution, they reestablish a soft baseline state. Here we show that sensing these mechanical changes in the microenvironment requires the mechanosensor YAP. YAP is induced upon activation and suppresses metabolic reprogramming of effector T cells. Unlike in other cell types in which YAP promotes proliferation, YAP in T cells suppresses proliferation in a stiffness-dependent manner by directly restricting the translocation of NFAT1 into the nucleus. YAP slows T cell responses in systemic viral infections and retards effector T cells in autoimmune diabetes. Our work reveals a paradigm whereby tissue mechanics fine-tune adaptive immune responses in health and disease.

4 March 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
ASAlexis Vanessa Stephens
Alexis Vanessa Stephens
TTTimothy J Thauland
Timothy J Thauland
GWGregory D Whitehill
Gregory D Whitehill
MGMaria I Garcia-Lloret
Maria I Garcia-Lloret
MBManish J Butte
Manish J Butte
Background. Mortality rates for disseminated coccidioidomycosis remain high despite modern antifungal therapies, resulting in substantial costs to society. We propose that immunomodulation as an adjunctive therapy with antifungals can improve clinical outcomes. Previous work suggested that treatment with interferon gamma or by blocking the IL-4/IL-13 receptor with dupilumab could improve clinical outcomes. Methods. We present a case series of 18 patients at UCLA with severe or persistent coccidioidomycosis receiving maximal antifungal treatment who received immunomodulatory therapy. Treatment selection based on the clinical context and intracellular cytokine staining that measured T helper cells producing interferon gamma or IL-4. Patients with severe disease received recombinant interferon gamma, while those showing Type-2 immune dysregulation were treated with dupilumab. Results. Patients receiving dupilumab showed a reduction in Type-2 T-cell responses. Importantly, 16 of the 18 patients survived (88%), with clinical outcomes improving relative to baseline in the majority. Conclusions. This case series provides evidence that patients with severe and/or disseminated coccidioidomycosis may benefit from immunomodulation. These positive outcomes support the consideration of off-label use of these medications. Clinical trials are warranted for interferon gamma in severe disease and dupilumab for disseminated disease when Type-2 immune dysregulation is present. Further research is needed to identify the specific patient populations that may benefit most from the addition of immunomodulatory medications.

28 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
TTTimothy J. Thauland
Timothy J. Thauland
SNSmriti S. Nagarajan
Smriti S. Nagarajan
ASAlexis V. Stephens
Alexis V. Stephens
SJSamantha L. Jensen
Samantha L. Jensen
ASAnviksha Srivastava
Anviksha Srivastava
MBManish J Butte
Manish J Butte
Background: Disseminated coccidioidomycosis (DCM) is an often fatal and otherwise intractable condition requiring lifelong antifungal treatment. We have previously shown that a deranged polarization of CD4 + T cells toward a Type-2 phenotype can exist in the context of DCM. Here we studied a large population of subjects to determine the frequency of abnormal Type-2 skewing of CD4 + T cells in patients with coccidioidomycosis and to identify underlying genetic mechanisms supporting this skew. Methods: We collected peripheral blood mononuclear cells from 204 patients with coccidioidomycosis, including 96 patients with disseminated disease. We measured immune phenotypes and cytokine production by CD4 + T cells from patients and healthy controls, and comparisons between groups were made based on disease severity and demographics. Whole genome sequencing was conducted on 149 individuals who also had cytokine profiling. Results: We found that ~20% of DCM patients had a CD4 + T-cell compartment that was abnormally skewed toward a Type-2 (IFN-γ-IL-4+) phenotype. Type-2 skewing was highly correlated with male sex, with 80% of moderately skewed (Th2:Th1 ratio > 1.5) and 100% of severely skewed (Th2:Th1 ratio > 2) patients being male. Co-culture of T cells with the IL4R/IL13R-blocking antibody dupilumab rectified their Th1/Th2 skewing. Sequencing revealed rare variants in genes involved in the IL-12-IFN-γ axis in several Type-2 skewed patients, and we validated one such variant in IFNGR1 as hypomorphic. Conclusion: Patients with DCM, especially those who are male, should be screened for Type-2 skewing of CD4 + T cells. Patients with Type-2 skewing should be additionally screened for genetic defects in the IL-12-IFN-γ axis. Our findings give a mechanistic rationale for exploring blockade of IL4R as a treatment option in Type-2 skewed patients with refractory coccidioidomycosis.

25 August 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
KTKavitha Thiagarajan
Kavitha Thiagarajan
HDHuan Vinh Dong
Huan Vinh Dong
CKCaroline Y. Kuo
Caroline Y. Kuo
TTTimothy J. Thauland
Timothy J. Thauland
SPSheeja T Pullarkat
Sheeja T Pullarkat
KNKarin Nielsen-Saines
Karin Nielsen-Saines
Signal transducer and activator of transcription 1 (STAT1) defects present with diverse clinical phenotypes. We describe an unusual genotype/phenotype: disseminated mycobacterial infection without chronic mucocutaneous candidiasis in the context of a pathogenic STAT1 gain-of-function variant (p.Lys388Glu). To our knowledge, this is the first report of such a case.